Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne
January 09, 2023 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health, is pleased to announce that in a...
Food Trends for 2023 Include Wellness Drinks, Gut Health, Confusion Around New Labels and Terminology
January 04, 2023 10:00 ET
|
International Food Information Council Foundation
Washington, D.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- With issues like inflation, supply chain disruptions, technological advancements and changing consumer desires, the food system is experiencing a...
Human Microbiome Global Market Report 2022: Increasing Collaboration Between Public-Private Organizations Catalyzes Growth
December 29, 2022 05:53 ET
|
Research and Markets
Dublin, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The "Human Microbiome Market Share, Size, Trends, Industry Analysis Report, By Product; By Application; By Disease, By Type; By Region; Segment Forecast,...
Global Microbiome Therapeutics Market Report 2022 - Players Include Evelo Biosciences, Ferring International, Immuron and LNC Therapeutics
December 20, 2022 04:33 ET
|
Research and Markets
Dublin, Dec. 20, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Microbiome...
Microbiome Sample Preparation Technology Market Report 2022: Rising Prevalence of Infectious Disease Fueling Demand
December 01, 2022 07:43 ET
|
Research and Markets
Dublin, Dec. 01, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Sample Preparation Technology Market Share, Size, Trends, Industry Analysis Report, By Product; By Workflow; By Application; By Disease; By...
2022 Insights on the Microbiome Therapeutics Global Market: Anticipated Future Developments and Trends
December 01, 2022 06:48 ET
|
Research and Markets
Dublin, Dec. 01, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics: Intellectual Property Landscape (Featuring Historical and Contemporary Patent Filing Trends, Prior Art Search Expressions,...
Global Microbiome Therapeutics Market Report 2022: Increasing Focus on Human Microbiome Therapeutics Development from Academics, Researchers & Biotechnology Firms
November 22, 2022 05:43 ET
|
Research and Markets
Dublin, Nov. 22, 2022 (GLOBE NEWSWIRE) -- The "Global Microbiome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Type (FMT v/s Microbiome...
Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results
November 10, 2022 07:00 ET
|
Finch Therapeutics Group, Inc.
Patient dosing underway in PRISM4 Phase 3 trial of CP101 in recurrent CDITopline PRISM4 data anticipated in H1 2024 Anticipated cash runway into Q2 2024 SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE...
Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022
November 09, 2022 08:30 ET
|
Summit Therapeutics Inc.
Menlo Park, California, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on...
Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference
November 09, 2022 08:00 ET
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...